Curanex Pharmaceuticals Inc (NASDAQ:CURX) Short Interest Up 96.7% in August

Curanex Pharmaceuticals Inc (NASDAQ:CURX) saw a significant growth in short interest in the month of August. As of August 14th, there was short interest totaling 24,375 shares, a growth of 96.7% from the July 30th total of 12,389 shares. Based on an average daily volume of 152,801 shares, the short-interest ratio is presently 0.2 days. Currently, 2.6% of the company’s shares are sold short.

Hedge Funds Weigh In On Curanex Pharmaceuticals

An institutional investor recently bought a new stake in Curanex Pharmaceuticals stock. Citadel Advisors LLC bought a new stake in shares of Curanex Pharmaceuticals Inc (NASDAQ:CURX) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 64,067 shares of the company’s stock, valued at approximately $46,000.

Curanex Pharmaceuticals Stock Performance

Curanex Pharmaceuticals stock opened at $4.56 on Friday. The company has a market capitalization of $7.16 million and a PE ratio of -0.58. Curanex Pharmaceuticals has a fifty-two week low of $3.58 and a fifty-two week high of $183.59. The firm has a 50 day moving average price of $4.49 and a 200 day moving average price of $6.54.

Curanex Pharmaceuticals (NASDAQ:CURX) last released its quarterly earnings results on Friday, August 14th. The company reported ($2.40) EPS for the quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Curanex Pharmaceuticals in a research note on Wednesday, July 29th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has a consensus rating of “Sell”.

About Curanex Pharmaceuticals

Curanex is a developmental stage pharmaceutical company dedicated to discovering, developing and commercializing innovative botanical drugs to treat patients suffering from inflammatory diseases. Our mission is to address significant unmet medical needs and improve patients’ lives by harnessing the power of natural substances. We are dedicated to discovering, developing and commercializing botanical medicines for treating patients with immune and inflammatory diseases and to develop therapies that may offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections.